millwallfan
02 Oct 2017
Disappointed I a man extremely disappointed with the performance of this company with what seemed to be an exceptional product with immense potential to both save many lives and also generate significant ongoing revenues and thus shareholder value. I wish management would provide an honest update of progress and future options.
claude reins
14 Sep 2017
Re: Lombard Looking at the quantity they have reduced, I would think that is a change in policy. Given the limited change in SP, I would expect that there will be a balancing movement by another major shareholder reported in the next few days.I still frate them a strong buy given the number of pisitive changes in movement towards a strong market position which we have seen in the last few days.- albeit some time off as all these things have long time scales.
Good money after bad
13 Sep 2017
Lombard If i am reading correctly Lombard have significantly reduced their holding. I would have thought it's worth an increase at these prices and have topped up. What do they know that I don't ?
claude reins
11 Sep 2017
Re: Qiagen This is more like it. It was the natural way to go. Qiagen, with 500k contacts, 4500 employees around the world, a lot of associated techniques into which Angle's programme will fit nicely and established strength in marketing. They are also saying that they will concentrate on the 2 big winners (or losers, depending on whether you are suffering from them!) breast cancer and prostatee cancer. I am surprised that the response hasnt seen a bigger jump in SP, since the fall in the last year has been substantial. What I dont know about is the list and strength of potential competitors, and I will be even more impressed when their attempt to patent their algorithm is successful. There is always the issue with this sort of company about how long it is going to take before they reach full commercialisation, but the NOMAD and Qiagen are major steps along the commercialisation road, and not least how much extra fundraising will be needed along the way.. I am getting quite excited as well as being positive about the role this type of diagnosis can play, especially in avoiding terrible biopsies and helping reduce misdiagnoses for these terrible medical conditions.
autpaxautbellum
11 Sep 2017
Qiagen This more than under rights the company.
autpaxautbellum
05 Sep 2017
Finncap New broker should give this a good shove now.
NoKitten
18 Aug 2017
might be of interest? [link] don't know how this might connect with Parsortix or whether it's a competing method.
asilad
03 Aug 2017
Re: Anyone else worried ? - Fundraising No questions raised about fundraising but there is clearly going to be one, hence the current shareprice weakness, as people wait to see at what price.Clinical trial money isn't to be had from the money tree unfortunately and AGL down to 3m.Superb long term buy after the fundraising and hopefully not snapped up too soon.
autpaxautbellum
01 Aug 2017
Re: Anyone else worried ? Webcast on the Angle website.No questions raised about finance post presentation.
Good money after bad
01 Aug 2017
Re: Anyone else worried ? missed the webcast....Did they say anythik about cash flow ? I assume they'll need to raise another £10-20m but at the current price I still see it as potential top up opportunity.
Field Marshall Lodl
27 Jul 2017
Re: Predicted to go far - but takes time Some really intelligent posts today. Perhaps the machine can be compared to some other clinical equipment that have entered the market. An MRI scanner is probably far more costly ergo sold in fewer numbers. You might argue all hospitals and clinics that need to detect could afford a Parsortrix machine.It is true that the machine if sold as a final revenue product, with perhaps some maintenance or support fee could be limited income-wise. A rental system could ensure income. As final revenue a spitball of 10,000 units sold over 3 years at £10K each would equate to a gross profit of £100mn or £33mn per year. Support fees of £1000 per machine per year = £10mn income.I have no idea what the unit estimates are and what if any commercial projections have been made. I believe trial machines should if not already be incorporated into the diagnostic process in oncology units. Given the unit's non invasive and uncomplex interaction with a patient it seems that this should be a process made available sooner rather than later. There can be no side effects — it isn't a drug.
millwallfan
27 Jul 2017
Re: Predicted to go far - but takes time Claude (or any other knowledgeable board member). You seem well versed on the detail of the company. Please do you know the answer to the following two questions (assuming all approvals and patents in place)? (1) The system uses a 'machine' to analyse the blood and isolate cancer cells. Would we 'sell' the machines or 'lease/rent' them to clinics/hospitals etc.(2) More critically, once such machines are in place, will the company make a charge 'per test'. This seems the critical business point I.e. Will the company generate Multiple , ongoing revenue stream which will expand and expand in both scope of cancer types and number of tests. Thanks in advance
claude reins
27 Jul 2017
Predicted to go far - but takes time I am a holder though this is not one of my larger holdings, and I am sitting on a paper loss currently.There are lots of conflicting issues with this stock which are reflected in this morning's results - where there are no surprises by the way. Lets take the plus points first - glass half full. The technology is being proven in more and more studies, in more and more countries - particularly the key ones in US, UK and Continental - for more and more cancer issues. particularly breast, prostate etc. Secondly, it is non-invasive, and because it depends on blood sampling, is cheap. Both of these aspects are incredibly important for cost and patient alike. The company is small, but has significant manahement shareholding - CEO has a near 10% share. It also has significant shareholding among some institutions. When it needed cash recently, it coudl raise it.Shares in issue: 74,815,774 10p OrdsSignificant Shareholders (>3%) Date Amount Holding %Jupiter Asset Management Limited 01/06/2016 7,404,584 9.90%Andrew Newland 27/10/2016 7,054,686 9.43%Lombard Odier Investment Managers group 03/04/2017 5,899,164 7.88%Fidelity International Limited 01/06/2016 2,325,581 3.11%The potential market size is huge if the company's statements are to be believed, and I have no reason why they should not be. The first thing you do as a business is to see whether your product is going to have a future.The company is working not only towards approval by the authorities - it claims that the first results in the US which will allow it to present to the FDA will be H1, 2018. It is also working on an algorithm which can be patented, presumably to differentiate it from potential competitors and give it a market leading proposition.The potential of the business for a takeover by one of the major pharmas should be very high. Reading an article in MoneyWeek recently, the M&A in biotech is huge. Within that, the dominant area is oncology - smack bang where Angle is!On the negative side, the SP has fallen signficantly since launch and also recently. Why? Impatient investors who can see faster opportuntiies elsewhere? A recognition that more money will need to be raised before significant commercialization? Almost certainly, although that may be balanced by a higher surety of success as the positive results, patens and regulatory approvals come in.In the meantime, the SP is very sensitive to really quite small changes in trades. Today so far, less than 1/4m against a 3 moth daily average of 200k and total shares of 65m. So in that sense, nothing to worry about when a few 'Ive had enough of this' PIs sell out.A fair review? Your thoughts? If you are a patient PI and have confidence (almost said 'faith' then!) in the comapny's proposition, then these exaggerated dips are a good opportuntiy to add to your holding. That's why I give it a buy. My best forecast - a takeover at a significant premium to the current price, probably sometime during 2018.
autpaxautbellum
27 Jul 2017
Re: Anyone else worried ? We will hopefully find out later in the webcast.
Good money after bad
27 Jul 2017
Anyone else worried ? Burning cash (as planned they say) with poor revenue growth. The money will runout before this takes off at this rate.
